Product Information
INVEGA ER 3 MG TABLET is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $12.4530 per EA under NDC 50458055001. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 19, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the paliperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
3 mg/1
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458055001
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
1/2/2026
Active Ingredients
PALIPERIDONEApproval Type
New Drug (NDA)
FDA Application
NDA021999FDA Approved
12/19/2006
TE Code
AB
On Market Since
12/19/2006
Pharmacological Classes
Price Statistics
The NADAC for INVEGA ER 3 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 41.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.4530 per EA |
|---|---|
| All-time high | $39.8104 (May 12, 2021) |
| All-time low | $11.7253 (Jul 20, 2022) |
| 52-week high | $12.4530 |
| 52-week low | $12.0849 |
| Median price | $27.3950 |
| Average price | $24.5850 |
| Largest weekly change | -70.0% (Oct 6, 2021) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 92% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
paliperidone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INVEGA ER 3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for INVEGA ER 3 MG TABLET, manufactured by Janssen Pharmaceuticals Inc., is $12.4530 per EA (NDC 50458055001), effective Sep 30, 2026.
How has the price of INVEGA ER 3 MG TABLET changed over time?
Over the history we have for it, the NADAC for INVEGA ER 3 MG TABLET has declined 41.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for INVEGA ER 3 MG TABLET?
Since Nov 28, 2013, the NADAC for INVEGA ER 3 MG TABLET has ranged from a low of $11.7253 (Jul 20, 2022) to a high of $39.8104 (May 12, 2021), with a median of $27.3950 per EA.
Are there cheaper alternatives to INVEGA ER 3 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PALIPERIDONE ER 3 MG TABLET, is $0.9719 per EA — about 92% below INVEGA ER 3 MG TABLET.
Who manufactures INVEGA ER 3 MG TABLET?
INVEGA ER 3 MG TABLET (NDC 50458055001) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.